{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:48:33Z","timestamp":1791254913114,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1980,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1097\/jto.0b013e3181e2f7fb","type":"journal-article","created":{"date-parts":[[2010,5,18]],"date-time":"2010-05-18T06:30:09Z","timestamp":1274164209000},"page":"1054-1059","source":"Crossref","is-referenced-by-count":58,"title":["A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung"],"prefix":"10.1016","volume":"5","author":[{"given":"Natasha B.","family":"Leighl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Raez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Massarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashat","family":"Gabrail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowell L.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy S.","family":"Albain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ostap","family":"Melnyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances A.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Sternas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judie","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenming","family":"Shun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy S.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib1","unstructured":"Aflibercept (AVE0005) Investigator's Brochure, 8 Ed. April 22, 2008."},{"issue":"15 suppl","key":"10.1097\/JTO.0b013e3181e2f7fb_bib2","article-title":"Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients with advanced solid malignancies","volume":"22","author":"Dupont","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.2009.22.9237","article-title":"Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors","volume":"28","author":"Lockhart","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s10434-001-0072-y","article-title":"Vascular endothelial growth factor expression in stage 1 non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis","volume":"8","author":"Han","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib5","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0022-5223(98)70398-8","article-title":"Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma","volume":"115","author":"Imoto","year":"1998","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"34 suppl","key":"10.1097\/JTO.0b013e3181e2f7fb_bib6","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0169-5002(01)00346-4","article-title":"Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis","volume":"2","author":"Niklinska","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1054\/bjoc.2001.1882","article-title":"The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer","volume":"85","author":"Kajita","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/jcp.2003.013508","article-title":"Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer","volume":"57","author":"Mineo","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.lungcan.2006.02.009","article-title":"Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer","volume":"53","author":"Seto","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/1097-0215(20001120)89:6<475::AID-IJC2>3.0.CO;2-T","article-title":"Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer","volume":"89","author":"Yuan","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/sj.bjc.6690058","article-title":"Expression of vascular endothelial growth factor mRNA in non-small -cell lung carcinomas","volume":"79","author":"Fontanini","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib12","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib13","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Randomized phase III trial of cisplatin\/gemcitabine with placebo or with bevacizumab as first-line therapy for non-squamous non-small cell lung cancer (AVAiL)","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib14","unstructured":"Hainsworth J, Lin M, O'Connor P, et al. A phase III multicenter, placebo-controlled, double-blind, randomized, clinical trial to evaluate the efficacy of bevacizumab in combination with erlotinib compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA). Plenary presentation, Chicago Multidisciplinary Symposium in Thoracic Oncology, November 13\u201315, 2008, Chicago Il."},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluation the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib16","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1200\/JCO.2007.13.9303","article-title":"Multicenter phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer","volume":"26","author":"Socinski","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1200\/JCO.2008.16.2545","article-title":"Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non-Small-Cell Lung Cancer","volume":"27","author":"Crabb","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11 suppl 4","key":"10.1097\/JTO.0b013e3181e2f7fb_bib18","first-page":"S263","article-title":"Phase II study of pazopanib given preoperatively in stage I-II NSCLC: a proof-of-concept study","volume":"3","author":"Altorki","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib19","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.7507","article-title":"Efficacy and safety of axitinib (AG-013736; AG) in patients with advanced non-small cell lung cancer: A phase II trial","volume":"25","author":"Schiller","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.7541","article-title":"Phase II open-label study to investigate efficacy and safety of PTK787\/ZK 222584 (PTK\/ZK) orally administered once daily or twice daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB\/IV non-small cell lung cancer (NSCLC)","volume":"25","author":"Gauler","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib22","article-title":"ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial","volume":"24","author":"Natale","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.7002","article-title":"Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma","volume":"24","author":"Gatzemeier","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.17119","article-title":"A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC)","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11 suppl 4","key":"10.1097\/JTO.0b013e3181e2f7fb_bib25","first-page":"S268","article-title":"Carboplatin\/paclitaxel with\/without sorafenib in chemonaive patients with stage IIIB\/IV non-small cell lung cancer: interim analysis results from a randomized phase III trial (ESCAPE)","volume":"3","author":"Hanna","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.8074","article-title":"Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer","volume":"26","author":"Sandler","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib27","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1158\/1078-0432.CCR-07-1154","article-title":"Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study","volume":"14","author":"Dowlati","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib28","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1158\/1078-0432.CCR-08-2568","article-title":"Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer","volume":"15","author":"Hanrahan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.7568","article-title":"Analyses of plasma cytokine\/angiogenic factors profile during preoperative treatment with pazopanib in early-stage non-small cell lung cancer","volume":"26","author":"Nikolinakos","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.2009.22.4279","article-title":"Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and\/or chemotherapy in patients with non-small-cell lung cancer","volume":"28","author":"Hanrahan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib31","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1200\/JCO.2007.13.5947","article-title":"VEGF polymorphisms and survival in early-stage non-small-cell lung cancer","volume":"26","author":"Heist","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib32","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","article-title":"Association of vascular endothelial growth factor receptor-2 polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: E2100","volume":"26","author":"Schneider","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.3543","article-title":"Association of diastolic blood pressure (dBP) \u226590 mmHg with overall survival in patients treated with axitinib (AG-013736)","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib34","volume":"27","author":"Goodwin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib35","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1200\/JCO.2009.25.4482","article-title":"Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with Bevacizumab","volume":"28","author":"Dahlberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e2f7fb_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.e19000","article-title":"MO19390 (SAiL): incidence of hemorrhage with first-line bevacizumab-based therapy in advanced non-small cell lung cancer","volume":"27","author":"Thatcher","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415305529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415305529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T23:24:13Z","timestamp":1635377053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415305529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S1556086415305529"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181e2f7fb","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}